Charles River, 's-Hertogenbosch, the Netherlands.
Charles River, 's-Hertogenbosch, the Netherlands.
Reprod Toxicol. 2019 Sep;88:56-66. doi: 10.1016/j.reprotox.2019.07.014. Epub 2019 Jul 23.
Recently several OECD test guidelines were updated to include thyroid hormone measurements for assessing endocrine disruptor potency, which led to an imperative need to align interpretation of these results by the different stakeholders. We therefore evaluated 124 repro screening studies, which showed in 38% of the studies a statistical significant finding for T4 in at least one treatment group, probably due to disturbances of normal homeostasis causing high variation. Consequently, for a thorough evaluation it is extremely important to take the historical control range into account. In conclusion, the current testing approach is not providing specific information needed to assess endocrine disruption, as too often a statistical significant finding is noted and as down-stream adverse effects are not evaluated. Therefore, major modifications are urgently needed. Instead of extending the in vivo experiments, it should be investigated if in vitro assessments will provide more relevant information on human endocrine disruptor potential.
最近，一些经合组织的测试指南已经更新，包括甲状腺激素测量，以评估内分泌干扰物的效力，这导致不同利益相关者必须对这些结果进行一致的解释。因此，我们评估了 124 项生殖筛选研究，其中 38%的研究在至少一个治疗组中发现 T4 的统计学显著结果，这可能是由于正常内稳态的紊乱导致了高变异性。因此，为了进行彻底的评估，考虑到历史控制范围是极其重要的。总之，目前的测试方法没有提供评估内分泌干扰所需的具体信息，因为经常注意到统计学上显著的发现，而且没有评估下游的不良反应。因此，迫切需要进行重大修改。与其扩展体内实验，不如研究体外评估是否会提供更多关于人类内分泌干扰物潜力的相关信息。
